Evidence map›Paper›PMID 30209161›Full record

Trial reportClinical cancer research : an official journal of the American Association for Cancer Research2019

Bram De Laere, Steffi Oeyen, Markus Mayrhofer, Tom Whitington, Pieter-Jan van Dam, Peter Van Oyen, Christophe Ghysel, Jozef Ampe, Piet Ost, Wim Demey and 27 more

Open access · bronzeAbstract readComparative StudyMulticenter StudyRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Clinical cancer research : an official journal of the American Association for Cancer Research, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 97 papers, 6 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
97citing papers in PubMed, 6 pooled it
15.6field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

97 citing papers in PubMed, 6 syntheses or guidelines pooled it, 167 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Evolution of AR and Non-AR Alterations in ctDNA of Patients with Metastatic Prostate Cancer Treated in the Phase III Alliance A031201 Trial.Clinical cancer research : an official journal of the American Association for Cancer Research · 2026
    Trial
  8. Trial
  9. Trial
  10. Trial
  11. Evaluating Immune Checkpoint Blockade in Metastatic Castration-Resistant Prostate Cancers with Deleterious CDK12 Alterations in the Phase 2 IMPACT Trial.Clinical cancer research : an official journal of the American Association for Cancer Research · 2024
    Trial
  12. Circulating and Intratumoral Adrenal Androgens Correlate with Response to Abiraterone in Men with Castration-Resistant Prostate Cancer.Clinical cancer research : an official journal of the American Association for Cancer Research · 2021
    Trial
  13. Single-Cell Circulating Tumor Cell Analysis Reveals Genomic Instability as a Distinctive Feature of Aggressive Prostate Cancer.Clinical cancer research : an official journal of the American Association for Cancer Research · 2020
    Trial
  14. Trial
  15. Trial
  16. Trial
  17. Review
  18. Article
  19. Observational
  20. Article

37 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

  • Commented on by
    2019
5 · Who and what money

Authors and funding

37 authors at 15 institutions in 4 countries.

Bram De LaereCenter for Oncological Research (CORE), University of Antwerp, Antwerp, Belgium. bramdelaere@gmail.com.
Steffi OeyenCenter for Oncological Research (CORE), University of Antwerp, Antwerp, Belgium.
Markus MayrhoferDepartment of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden.
Tom WhitingtonDepartment of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden.
Pieter-Jan van DamCenter for Oncological Research (CORE), University of Antwerp, Antwerp, Belgium.ORCID 0000-0001-9074-8271
Peter Van OyenDepartment of Urology, AZ Sint-Jan, Brugge, Belgium.
Christophe GhyselDepartment of Urology, AZ Sint-Jan, Brugge, Belgium.
Jozef AmpeDepartment of Urology, AZ Sint-Jan, Brugge, Belgium.
Piet OstDepartment of Radiation Oncology, Ghent University Hospital, Ghent, Belgium.ORCID 0000-0002-2203-4848
Wim DemeyDepartment of Oncology, AZ KLINA, Brasschaat, Belgium.
Lucien HoekxDepartment of Urology, Antwerp University Hospital, Antwerp, Belgium.
Dirk SchrijversDepartment of Oncology, ZNA Middelheim, Antwerp, Belgium.
Barbara BrouwersDepartment of Oncology, AZ Sint-Jan, Brugge, Belgium.
Willem LybaertDepartment of Oncology, AZ Nikolaas, Sint-Niklaas, Belgium.
Els G EveraertDepartment of Oncology, AZ Nikolaas, Sint-Niklaas, Belgium.ORCID 0000-0002-8874-6602
Daan De MaeseneerDepartment of Oncology, AZ Sint-Lucas, Brugge, Belgium.
Michiel StrijbosDepartment of Oncology, AZ KLINA, Brasschaat, Belgium.
Alain BolsDepartment of Oncology, AZ Sint-Jan, Brugge, Belgium.
Karen FransisDepartment of Urology, Antwerp University Hospital, Antwerp, Belgium.
Nick BeijeMedical Oncology and Cancer Genomics Netherlands, Erasmus MC Cancer Institute, Erasmus University Medical Center, Rotterdam, the Netherlands.ORCID 0000-0001-5462-9486
Inge E de KruijffMedical Oncology and Cancer Genomics Netherlands, Erasmus MC Cancer Institute, Erasmus University Medical Center, Rotterdam, the Netherlands.
Valerie van DamCenter for Oncological Research (CORE), University of Antwerp, Antwerp, Belgium.ORCID 0000-0001-9074-8271
Anja BrouwerCenter for Oncological Research (CORE), University of Antwerp, Antwerp, Belgium.
Dirk GoossensAgilent Technologies, Niel, Belgium.ORCID 0000-0002-2080-7464
Lien HeyrmanAgilent Technologies, Niel, Belgium.
Gert G Van den EyndenDepartment of Pathology, GZA Hospitals Sint-Augustinus, Antwerp, Belgium.
Annemie RuttenDepartment of Oncology, GZA Hospitals Sint-Augustinus, Antwerp, Belgium.
Jurgen Del FaveroAgilent Technologies, Niel, Belgium.ORCID 0000-0002-7427-7489
Mattias RantalainenDepartment of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden.
Prabhakar RajanCentre for Molecular Oncology, Barts Cancer Institute, Queen Mary University of London, London, United Kingdom.ORCID 0000-0001-8064-9878
Stefan SleijferMedical Oncology and Cancer Genomics Netherlands, Erasmus MC Cancer Institute, Erasmus University Medical Center, Rotterdam, the Netherlands.
Anders UllénDepartment of Oncology-Pathology, Karolinska Institutet and University Hospital, Stockholm, Sweden.
Jeffrey YachninDepartment of Oncology-Pathology, Karolinska Institutet and University Hospital, Stockholm, Sweden.
Henrik GrönbergDepartment of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden.ORCID 0000-0002-1073-2753
Steven J Van LaereCenter for Oncological Research (CORE), University of Antwerp, Antwerp, Belgium.
Johan LindbergDepartment of Medical Epidemiology and Biostatistics, Science for Life Laboratory, Karolinska Institutet, Stockholm, Sweden.
Luc Y DirixCenter for Oncological Research (CORE), University of Antwerp, Antwerp, Belgium.
University of Antwerp · BEAZ Sint-Jan · BEKarolinska Institutet · SEAgilent Technologies (Belgium) · BEErasmus MC Cancer Institute · NLAntwerp University Hospital · BEAZ Klina · BEGZA Ziekenhuizen Campus Sint-Augustinus · BEKarolinska University Hospital · SEVlaamse Vereniging voor Obstetrie en Gynaecolo · BEAZ Sint-Lucas · BEGhent University Hospital · BEQueen Mary University of London · GBScience for Life Laboratory · SEZNA Middelheim Hospital · BE

Funding

Cancer Research UK 15339Cancer Research UK C19198/A1533
6 · The paper itself

Abstract

purposeTo infer the prognostic value of simultaneous androgen receptor (

resultsOverall, no single

conclusionsIn an all-comer cohort, tumor burden estimates and

Indexed as

AgedAged, 80 and overAndrogen Receptor AntagonistsAndrostenesAntineoplastic AgentsBenzamidesBiomarkers, TumorCirculating Tumor DNADisease-Free SurvivalDrug Resistance, NeoplasmFollow-Up StudiesHumansKaplan-Meier EstimateLiquid BiopsyMaleNeoplastic Cells, CirculatingabirateroneAndrogen Receptor AntagonistsAndrostenesAntineoplastic AgentsAR protein, humanBenzamidesBiomarkers, TumorCirculating Tumor DNAenzalutamideNitrilesPhenylthiohydantoinReceptors, AndrogenTP53 protein, humanTumor Suppressor Protein p53

Identifiers

PMID30209161
PMCPMC6330086
OpenAlexW2892240038

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.